BASILEA PHARMACEUTICA
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.
BASILEA PHARMACEUTICA
Industry:
Biotechnology Commercial Pharmaceutical
Founded:
2000-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.basilea.com
Total Employee:
101+
Status:
Active
Contact:
41616061112
Total Funding:
84.69 M USD
Technology used in webpage:
Domain Not Resolving HSTS Organization Schema ReCAPTCHA V2 IIS PostalAddress Schema DigiCert SSL Smart App Banner IIS 8 Place Schema
Similar Organizations
Actimed Therapeutics
Actimed Therapeutics is a clinical stage biopharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company
Kazia Therapeutics
Kazia Therapeutics is an oncology focused biotechnology company.
Oncimmune
Oncimmune engaged in developing and commercializing its EarlyCDT platform technology.
Current Advisors List
Board_member
Board_member
Board_member
2007-01-01
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Ronald Scott Chief Executive Officer @ Basilea Pharmaceutica
Chief Executive Officer
Marc Engelhardt Head of Development @ Basilea Pharmaceutica
Head of Development
2012-11-01
Ingrid Heinze-Krauss CTO @ Basilea Pharmaceutica
CTO
Martin Nicklasson Director of the Board @ Basilea Pharmaceutica
Director of the Board
2013-04-01
Adrian Bruengger Head of Discovery Informatics @ Basilea Pharmaceutica
Head of Discovery Informatics
2004-08-01
Agnes Aebi Clinical Operations Global Program Leader @ Basilea Pharmaceutica
Clinical Operations Global Program Leader
2018-01-01
Mark Jones Head of Project Management & Head of Preclinical Development @ Basilea Pharmaceutica
Head of Project Management & Head of Preclinical Development
2018-01-01
David Veitch Chief Executive Officer @ Basilea Pharmaceutica
Chief Executive Officer
2018-04-01
Jan Posthumus Head of Global Market Access, Market Research and New Product Commercialization @ Basilea Pharmaceutica
Head of Global Market Access, Market Research and New Product Commercialization
2017-12-01
Andreas Kümin Head of Corporate Development @ Basilea Pharmaceutica
Head of Corporate Development
2019-04-01
Stock Details
Investors List
CARB-X
CARB-X investment in Grant - Basilea Pharmaceutica
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Basilea Pharmaceutica
Biomedical Advanced Research and Development Authority (BARDA)
Biomedical Advanced Research and Development Authority (BARDA) investment in Grant - Basilea Pharmaceutica
CARB-X
CARB-X investment in Grant - Basilea Pharmaceutica
Official Site Inspections
http://www.basilea.com Semrush global rank: 3.71 M Semrush visits lastest month: 3.29 K
- Host name: basilealb12.nine.ch
- IP address: 5.148.179.212
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Basilea Pharmaceutica"
Basilea.com : Basilea
Basilea is located in the Basel area, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). CEO David Veitch | Half-Year Report 2024. Play. News ... Organization. What we do. …See details»
Investor center : Basilea
Dec 23, 2024 In July 2020, Basilea issued CHF 97.085 million convertible bonds due 2027 ("New Bonds", ISIN: CH0554992062; SSN: 55'499'206) and repurchased CHF 47.085 million of its CHF 200 million existing convertible …See details»
Basilea Pharmaceutica Ltd. – Swiss Biotech
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) is a commercial-stage biopharmaceutical company headquartered in Switzerland. Basilea is committed to discovering, developing and …See details»
Basilea Pharmaceutica - Crunchbase Company Profile & Funding
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial …See details»
Basilea Pharmaceutica - Wikipedia
Basilea Pharmaceutica was founded in 2000 as a corporate spin-off of the pharmaceutical company Roche. [5]In 2002, Chinese subsidiary Basilea Pharmaceutica China Ltd. (BPC) was …See details»
Basilea Pharmaceutica - Overview, News & Similar companies
Oct 28, 2020 Basilea Pharmaceutica contact info: Phone number: +41 616061111 Website: www.basilea.com What does Basilea Pharmaceutica do? Founded in 2000, Basilea …See details»
Basilea Pharmaceutica AG
Basilea’s relationship with BARDA stretches back to 2013 when the agency committed $89 million in funding toward the antibiotic BAL30072—although the biotech went on to scrap the …See details»
Basilea enters into agreement with BARDA to develop novel …
Sep 19, 2024 Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement …See details»
News - Basilea
February 15, 2022 Full Year Report 2021 . Who we are. Basilea at a glanceSee details»
Basilea is awarded additional CARB-X funding to develop new …
Dec 23, 2024 Basilea has acquired the LptA antibiotics program from Spexis AG in early 2024. In April this year, Basilea announced that it was awarded an initial CARB-X grant of up to USD …See details»
CARB-X is funding Basilea Pharmaceutica to develop a new class …
Basilea’s new drug targets drug-resistant bacteria identified by the World Health Organization (WHO) as ‘critical’ pathogens against which new antibiotics are urgently needed (BOSTON: …See details»
Basilea is awarded additional CARB-X funding to develop new
Dec 23, 2024 Basilea has acquired the LptA antibiotics program from Spexis AG in early 2024. In April this year, Basilea announced that it was awarded an initial CARB-X grant of up to USD …See details»
Basilea is awarded additional CARB-X funding to develop new …
Dec 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial …See details»
Basilea Pharmaceutica International Ltd - BIO International …
Basilea Pharmaceutica International Ltd. Biotech or pharma, therapeutic R&D Address Switzerland Contact Exhibitor. Full Name * Email Address * Contact Message * Please enter …See details»
Reports Archive : Basilea
Organization. What we do. Our portfolio. Disease areas. Our products and pipeline. Investor center. Investing in Basilea. Convertible bonds. Current presentation. Financial reports. ...See details»
Basilea Pharmaceutica - Contacts, Employees, Board Members
Basilea Pharmaceutica has 15 current employee profiles, including Chief Executive Officer Ronald Scott. Basilea Pharmaceutica has 8 board members and advisors, including Domenico Scala . …See details»
Glioblastoma Foundation® Acquires Drug Lisavanbulin
Oct 24, 2024 Oncology drug displays potential as therapy for a subset of glioblastoma patients [Durham, NC, October 24, 2024] The Glioblastoma Foundation, the leading national nonprofit …See details»
The Basel Committee - overview - Bank for International Settlements
Dec 11, 2024 The Basel Committee on Banking Supervision (BCBS) is the primary global standard setter for the prudential regulation of banks and provides a forum for regular …See details»
News - Basilea
Replay. Webcast presentation. For questions, please additionally dial-in via phone. +41 (0) 58 310 50 00 (Europe and ROW) +1 (1) 866 291 41 66 (USA)See details»
English soccer executive Kay Cossington to launch new Bay …
1 day ago The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, …See details»